JP2013537210A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013537210A5 JP2013537210A5 JP2013528663A JP2013528663A JP2013537210A5 JP 2013537210 A5 JP2013537210 A5 JP 2013537210A5 JP 2013528663 A JP2013528663 A JP 2013528663A JP 2013528663 A JP2013528663 A JP 2013528663A JP 2013537210 A5 JP2013537210 A5 JP 2013537210A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- pyridin
- methyl
- substituted
- dihydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 79
- 150000001875 compounds Chemical class 0.000 claims description 30
- 125000005843 halogen group Chemical group 0.000 claims description 30
- 150000003839 salts Chemical class 0.000 claims description 28
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 20
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 16
- 125000005842 heteroatom Chemical group 0.000 claims description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 12
- 125000001424 substituent group Chemical group 0.000 claims description 12
- -1 —OH Chemical group 0.000 claims description 11
- 125000000217 alkyl group Chemical group 0.000 claims description 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 9
- 239000002246 antineoplastic agent Substances 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 7
- 208000035475 disorder Diseases 0.000 claims description 7
- 230000001404 mediated effect Effects 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 208000011580 syndromic disease Diseases 0.000 claims description 7
- 239000000654 additive Substances 0.000 claims description 6
- 230000000996 additive effect Effects 0.000 claims description 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 125000001624 naphthyl group Chemical group 0.000 claims description 6
- 101150051357 CYP17A1 gene Proteins 0.000 claims description 5
- 230000005764 inhibitory process Effects 0.000 claims description 5
- KJNWSJSISDSMFY-UHFFFAOYSA-N 2-(4-methylpyridin-3-yl)-3,4-dihydro-[1]benzothiolo[3,2-c]pyridin-1-one Chemical compound CC1=CC=NC=C1N1C(=O)C(C2=CC=CC=C2S2)=C2CC1 KJNWSJSISDSMFY-UHFFFAOYSA-N 0.000 claims description 4
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 4
- 230000001028 anti-proliverative effect Effects 0.000 claims description 4
- 229940127089 cytotoxic agent Drugs 0.000 claims description 4
- 229910052805 deuterium Inorganic materials 0.000 claims description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
- NYWDCPLDDJAWEB-UHFFFAOYSA-N 1-ethyl-6-(4-methylpyridin-3-yl)-4,5-dihydropyrrolo[2,3-c]pyridin-7-one Chemical compound O=C1C=2N(CC)C=CC=2CCN1C1=CN=CC=C1C NYWDCPLDDJAWEB-UHFFFAOYSA-N 0.000 claims description 2
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 claims description 2
- CHTFAUNNEPNVAA-UHFFFAOYSA-N 2-(3-methylimidazol-4-yl)-7-(trifluoromethyl)-3,4-dihydroisoquinolin-1-one Chemical compound CN1C=NC=C1N1C(=O)C2=CC(C(F)(F)F)=CC=C2CC1 CHTFAUNNEPNVAA-UHFFFAOYSA-N 0.000 claims description 2
- YFPFUFGVIVAGMH-UHFFFAOYSA-N 2-(4-cyclopropylpyridin-3-yl)-3,4-dihydro-[1]benzothiolo[3,2-c]pyridin-1-one Chemical compound C1CC=2SC3=CC=CC=C3C=2C(=O)N1C1=CN=CC=C1C1CC1 YFPFUFGVIVAGMH-UHFFFAOYSA-N 0.000 claims description 2
- FUWKIUPNPQWCIJ-UHFFFAOYSA-N 2-(4-cyclopropylpyridin-3-yl)-7-(trifluoromethyl)-3,4-dihydroisoquinolin-1-one Chemical compound O=C1C2=CC(C(F)(F)F)=CC=C2CCN1C1=CN=CC=C1C1CC1 FUWKIUPNPQWCIJ-UHFFFAOYSA-N 0.000 claims description 2
- KJVKJNONSDJBLU-UHFFFAOYSA-N 2-(4-methylpyridin-3-yl)-3,4-dihydrobenzo[h]isoquinolin-1-one Chemical compound CC1=CC=NC=C1N1C(=O)C2=C3C=CC=CC3=CC=C2CC1 KJVKJNONSDJBLU-UHFFFAOYSA-N 0.000 claims description 2
- MMRQPEMIYFAXGI-UHFFFAOYSA-N 2-(4-methylpyridin-3-yl)-5h-pyrido[4,3-b]indol-1-one Chemical compound CC1=CC=NC=C1N1C(=O)C(C2=CC=CC=C2N2)=C2C=C1 MMRQPEMIYFAXGI-UHFFFAOYSA-N 0.000 claims description 2
- XRDVWMVOUCOYDZ-UHFFFAOYSA-N 2-(4-methylpyridin-3-yl)-6-(trifluoromethyl)-3,4-dihydroisoquinolin-1-one Chemical compound CC1=CC=NC=C1N1C(=O)C2=CC=C(C(F)(F)F)C=C2CC1 XRDVWMVOUCOYDZ-UHFFFAOYSA-N 0.000 claims description 2
- RBAAUSWTBLZKKC-UHFFFAOYSA-N 2-(4-methylpyridin-3-yl)-7-(trifluoromethoxy)-3,4-dihydroisoquinolin-1-one Chemical compound CC1=CC=NC=C1N1C(=O)C2=CC(OC(F)(F)F)=CC=C2CC1 RBAAUSWTBLZKKC-UHFFFAOYSA-N 0.000 claims description 2
- WCWOFALHWCXBJZ-UHFFFAOYSA-N 2-(4-methylpyridin-3-yl)-7-(trifluoromethyl)-3,4-dihydroisoquinolin-1-one Chemical compound CC1=CC=NC=C1N1C(=O)C2=CC(C(F)(F)F)=CC=C2CC1 WCWOFALHWCXBJZ-UHFFFAOYSA-N 0.000 claims description 2
- LIZWBPASXMNTKX-UHFFFAOYSA-N 2-[4-[(cyclopropylamino)methyl]pyridin-3-yl]-7-(trifluoromethyl)-3,4-dihydroisoquinolin-1-one Chemical compound O=C1C2=CC(C(F)(F)F)=CC=C2CCN1C1=CN=CC=C1CNC1CC1 LIZWBPASXMNTKX-UHFFFAOYSA-N 0.000 claims description 2
- CBVWKRQTHAPCNI-UHFFFAOYSA-N 2-isoquinolin-4-yl-7-(trifluoromethyl)-3,4-dihydroisoquinolin-1-one Chemical compound C1=CC=C2C(N3CCC4=CC=C(C=C4C3=O)C(F)(F)F)=CN=CC2=C1 CBVWKRQTHAPCNI-UHFFFAOYSA-N 0.000 claims description 2
- INVBCRJJXNQCCI-UHFFFAOYSA-N 2-pyridin-3-yl-7-(trifluoromethyl)-3,4-dihydroisoquinolin-1-one Chemical compound O=C1C2=CC(C(F)(F)F)=CC=C2CCN1C1=CC=CN=C1 INVBCRJJXNQCCI-UHFFFAOYSA-N 0.000 claims description 2
- NMJVMBXBELEMDN-UHFFFAOYSA-N 2-pyridin-3-yl-7-(trifluoromethyl)isoquinolin-1-one Chemical compound O=C1C2=CC(C(F)(F)F)=CC=C2C=CN1C1=CC=CN=C1 NMJVMBXBELEMDN-UHFFFAOYSA-N 0.000 claims description 2
- GILUZPYWTVJOIY-UHFFFAOYSA-N 3-methyl-2-(4-methylpyridin-3-yl)-7-(trifluoromethyl)-3,4-dihydroisoquinolin-1-one Chemical compound CC1CC2=CC=C(C(F)(F)F)C=C2C(=O)N1C1=CN=CC=C1C GILUZPYWTVJOIY-UHFFFAOYSA-N 0.000 claims description 2
- YNSUWACVMIEBJI-UHFFFAOYSA-N 3-methyl-2-pyridin-3-yl-7-(trifluoromethyl)-3,4-dihydroisoquinolin-1-one Chemical compound CC1CC2=CC=C(C(F)(F)F)C=C2C(=O)N1C1=CC=CN=C1 YNSUWACVMIEBJI-UHFFFAOYSA-N 0.000 claims description 2
- WLDDLIXKUQGYSJ-UHFFFAOYSA-N 5-ethyl-8-fluoro-2-(4-methylpyridin-3-yl)-3,4-dihydropyrido[4,3-b]indol-1-one Chemical compound O=C1C=2C3=CC(F)=CC=C3N(CC)C=2CCN1C1=CN=CC=C1C WLDDLIXKUQGYSJ-UHFFFAOYSA-N 0.000 claims description 2
- PPWMEEVSDCDXLR-UHFFFAOYSA-N 6,7-dichloro-2-[4-(trifluoromethyl)pyridin-3-yl]-3,4-dihydroisoquinolin-1-one Chemical compound FC(F)(F)C1=CC=NC=C1N1C(=O)C2=CC(Cl)=C(Cl)C=C2CC1 PPWMEEVSDCDXLR-UHFFFAOYSA-N 0.000 claims description 2
- AGMUWKFIQCKPFM-UHFFFAOYSA-N 6,7-difluoro-2-(4-methylpyridin-3-yl)-3,4-dihydroisoquinolin-1-one Chemical compound CC1=CC=NC=C1N1C(=O)C2=CC(F)=C(F)C=C2CC1 AGMUWKFIQCKPFM-UHFFFAOYSA-N 0.000 claims description 2
- GKYWPUPAVWIAFH-UHFFFAOYSA-N 6-chloro-7-(trifluoromethyl)-2-[4-(trifluoromethyl)pyridin-3-yl]-3,4-dihydroisoquinolin-1-one Chemical compound FC(F)(F)C1=CC=NC=C1N1C(=O)C2=CC(C(F)(F)F)=C(Cl)C=C2CC1 GKYWPUPAVWIAFH-UHFFFAOYSA-N 0.000 claims description 2
- PHVQVPMJINTFAW-UHFFFAOYSA-N 6-fluoro-7-iodo-2-[4-(trifluoromethyl)pyridin-3-yl]-3,4-dihydroisoquinolin-1-one Chemical compound O=C1C=2C=C(I)C(F)=CC=2CCN1C1=CN=CC=C1C(F)(F)F PHVQVPMJINTFAW-UHFFFAOYSA-N 0.000 claims description 2
- NPGTWYOGFSOHCA-UHFFFAOYSA-N 6-hydroxy-2-(4-methylpyridin-3-yl)-3,4-dihydroisoquinolin-1-one Chemical compound CC1=CC=NC=C1N1C(=O)C2=CC=C(O)C=C2CC1 NPGTWYOGFSOHCA-UHFFFAOYSA-N 0.000 claims description 2
- INRNWAMACSZKBL-UHFFFAOYSA-N 6-methoxy-2-(4-methylpyridin-3-yl)-3,4-dihydroisoquinolin-1-one Chemical compound C1CC2=CC(OC)=CC=C2C(=O)N1C1=CN=CC=C1C INRNWAMACSZKBL-UHFFFAOYSA-N 0.000 claims description 2
- KYWSKIFIWGWSHI-UHFFFAOYSA-N 7-(4-methylpyridin-3-yl)-5,6-dihydro-1h-pyrazolo[4,3-g]isoquinolin-8-one Chemical compound CC1=CC=NC=C1N1C(=O)C2=CC(NN=C3)=C3C=C2CC1 KYWSKIFIWGWSHI-UHFFFAOYSA-N 0.000 claims description 2
- ZZXDILUZKNPOER-UHFFFAOYSA-N 7-(trifluoromethyl)-2-[4-(trifluoromethyl)pyridin-3-yl]-3,4-dihydroisoquinolin-1-one Chemical compound O=C1C2=CC(C(F)(F)F)=CC=C2CCN1C1=CN=CC=C1C(F)(F)F ZZXDILUZKNPOER-UHFFFAOYSA-N 0.000 claims description 2
- HARSQVGPUSTXEX-UHFFFAOYSA-N 7-chloro-2-(4-cyclopropylpyridin-3-yl)-1-oxo-3,4-dihydroisoquinoline-6-carbonitrile Chemical compound C1CC=2C=C(C#N)C(Cl)=CC=2C(=O)N1C1=CN=CC=C1C1CC1 HARSQVGPUSTXEX-UHFFFAOYSA-N 0.000 claims description 2
- FYGAMINWRVCJJS-UHFFFAOYSA-N 7-chloro-2-(4-cyclopropylpyridin-3-yl)-3,4-dihydroisoquinolin-1-one Chemical compound O=C1C2=CC(Cl)=CC=C2CCN1C1=CN=CC=C1C1CC1 FYGAMINWRVCJJS-UHFFFAOYSA-N 0.000 claims description 2
- OWZDDFPXTKKNFD-UHFFFAOYSA-N 7-chloro-2-(4-cyclopropylpyridin-3-yl)-6-fluoro-3,4-dihydroisoquinolin-1-one Chemical compound O=C1C=2C=C(Cl)C(F)=CC=2CCN1C1=CN=CC=C1C1CC1 OWZDDFPXTKKNFD-UHFFFAOYSA-N 0.000 claims description 2
- GVJXKVRIPWVUKI-UHFFFAOYSA-N 7-chloro-2-(4-cyclopropylpyridin-3-yl)-6-methoxy-3,4-dihydroisoquinolin-1-one Chemical compound O=C1C=2C=C(Cl)C(OC)=CC=2CCN1C1=CN=CC=C1C1CC1 GVJXKVRIPWVUKI-UHFFFAOYSA-N 0.000 claims description 2
- YGPCTKLCAYLNMW-UHFFFAOYSA-N 7-chloro-2-(4-ethylpyridin-3-yl)-3,4-dihydroisoquinolin-1-one Chemical compound CCC1=CC=NC=C1N1C(=O)C2=CC(Cl)=CC=C2CC1 YGPCTKLCAYLNMW-UHFFFAOYSA-N 0.000 claims description 2
- GKDSIVWNGIXYRF-UHFFFAOYSA-N 7-chloro-2-(4-methylpyridin-3-yl)-1-oxo-3,4-dihydroisoquinoline-6-carbonitrile Chemical compound CC1=CC=NC=C1N1C(=O)C2=CC(Cl)=C(C#N)C=C2CC1 GKDSIVWNGIXYRF-UHFFFAOYSA-N 0.000 claims description 2
- KKIAGMGEWHTJPO-UHFFFAOYSA-N 7-chloro-2-(4-methylpyridin-3-yl)-3,4-dihydroisoquinolin-1-one Chemical compound CC1=CC=NC=C1N1C(=O)C2=CC(Cl)=CC=C2CC1 KKIAGMGEWHTJPO-UHFFFAOYSA-N 0.000 claims description 2
- DWOQLJMJDQSCNW-UHFFFAOYSA-N 7-chloro-2-pyridin-3-yl-3,4-dihydroisoquinolin-1-one Chemical compound O=C1C2=CC(Cl)=CC=C2CCN1C1=CC=CN=C1 DWOQLJMJDQSCNW-UHFFFAOYSA-N 0.000 claims description 2
- BOZRJLNRFSPCQB-UHFFFAOYSA-N 7-chloro-6-fluoro-2-(4-methylpyridin-3-yl)-3,4-dihydroisoquinolin-1-one Chemical compound CC1=CC=NC=C1N1C(=O)C2=CC(Cl)=C(F)C=C2CC1 BOZRJLNRFSPCQB-UHFFFAOYSA-N 0.000 claims description 2
- HFVYCXGEFVOVGP-UHFFFAOYSA-N 7-chloro-6-methoxy-2-(4-methylpyridin-3-yl)-3,4-dihydroisoquinolin-1-one Chemical compound O=C1C=2C=C(Cl)C(OC)=CC=2CCN1C1=CN=CC=C1C HFVYCXGEFVOVGP-UHFFFAOYSA-N 0.000 claims description 2
- BTGCCXAPOLNLIU-UHFFFAOYSA-N 7-chloro-8-fluoro-2-(4-methylpyridin-3-yl)-3,4-dihydroisoquinolin-1-one Chemical compound CC1=CC=NC=C1N1C(=O)C2=C(F)C(Cl)=CC=C2CC1 BTGCCXAPOLNLIU-UHFFFAOYSA-N 0.000 claims description 2
- LUYRWOIXJQEQJJ-UHFFFAOYSA-N 7-hydroxy-2-(4-methylpyridin-3-yl)-3,4-dihydroisoquinolin-1-one Chemical compound CC1=CC=NC=C1N1C(=O)C2=CC(O)=CC=C2CC1 LUYRWOIXJQEQJJ-UHFFFAOYSA-N 0.000 claims description 2
- FJJXPIINPAJETC-UHFFFAOYSA-N 7-methoxy-2-(4-methylpyridin-3-yl)-3,4-dihydroisoquinolin-1-one Chemical compound O=C1C2=CC(OC)=CC=C2CCN1C1=CN=CC=C1C FJJXPIINPAJETC-UHFFFAOYSA-N 0.000 claims description 2
- PIDQGQWVYWFYSG-UHFFFAOYSA-N 8-(4-methylpyridin-3-yl)-6,7-dihydro-[1,3]thiazolo[4,5-h]isoquinolin-9-one Chemical compound CC1=CC=NC=C1N1C(=O)C2=C3SC=NC3=CC=C2CC1 PIDQGQWVYWFYSG-UHFFFAOYSA-N 0.000 claims description 2
- WFOZMDWGNMXUQA-UHFFFAOYSA-N 8-chloro-7-fluoro-2-(4-methylpyridin-3-yl)-3,4-dihydroisoquinolin-1-one Chemical compound CC1=CC=NC=C1N1C(=O)C2=C(Cl)C(F)=CC=C2CC1 WFOZMDWGNMXUQA-UHFFFAOYSA-N 0.000 claims description 2
- KSEIXXIELGDOEJ-UHFFFAOYSA-N 8-fluoro-2-(4-methylpyridin-3-yl)-3,4-dihydro-[1]benzothiolo[3,2-c]pyridin-1-one Chemical compound CC1=CC=NC=C1N1C(=O)C(C2=CC(F)=CC=C2S2)=C2CC1 KSEIXXIELGDOEJ-UHFFFAOYSA-N 0.000 claims description 2
- ORCBHPRQSKOSRD-UHFFFAOYSA-N 8-fluoro-2-(4-methylpyridin-3-yl)-4,5-dihydro-3h-pyrido[4,3-b]indol-1-one Chemical compound CC1=CC=NC=C1N1C(=O)C(C2=CC(F)=CC=C2N2)=C2CC1 ORCBHPRQSKOSRD-UHFFFAOYSA-N 0.000 claims description 2
- HSUMPWPEBDDDQR-UHFFFAOYSA-N 8-fluoro-2-(4-methylpyridin-3-yl)-7-(trifluoromethyl)-3,4-dihydroisoquinolin-1-one Chemical compound CC1=CC=NC=C1N1C(=O)C2=C(F)C(C(F)(F)F)=CC=C2CC1 HSUMPWPEBDDDQR-UHFFFAOYSA-N 0.000 claims description 2
- VWGCTIGAUYFUSC-UHFFFAOYSA-N 9-ethyl-2-(4-methylpyridin-3-yl)-3,4-dihydropyrido[3,4-b]indol-1-one Chemical compound C12=CC=CC=C2N(CC)C(C2=O)=C1CCN2C1=CN=CC=C1C VWGCTIGAUYFUSC-UHFFFAOYSA-N 0.000 claims description 2
- SPLWRYXPNYNVAS-UHFFFAOYSA-N 9-ethyl-3-methyl-2-(4-methylpyridin-3-yl)-3,4-dihydropyrido[3,4-b]indol-1-one Chemical compound C12=CC=CC=C2N(CC)C(C2=O)=C1CC(C)N2C1=CN=CC=C1C SPLWRYXPNYNVAS-UHFFFAOYSA-N 0.000 claims description 2
- KYRLEWPUPDEOSS-UHFFFAOYSA-N 9-ethyl-3-methyl-2-pyridin-3-yl-3,4-dihydropyrido[3,4-b]indol-1-one Chemical compound C12=CC=CC=C2N(CC)C(C2=O)=C1CC(C)N2C1=CC=CN=C1 KYRLEWPUPDEOSS-UHFFFAOYSA-N 0.000 claims description 2
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000000336 imidazol-5-yl group Chemical group [H]N1C([H])=NC([H])=C1[*] 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
- 229940124766 Cyp17 inhibitor Drugs 0.000 claims 2
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 238000002648 combination therapy Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 238000000034 method Methods 0.000 description 5
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 1
- 125000004548 quinolin-3-yl group Chemical group N1=CC(=CC2=CC=CC=C12)* 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN2719/CHE/2010 | 2010-09-16 | ||
| IN2719CH2010 | 2010-09-16 | ||
| PCT/EP2011/065965 WO2012035078A1 (en) | 2010-09-16 | 2011-09-14 | 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013537210A JP2013537210A (ja) | 2013-09-30 |
| JP2013537210A5 true JP2013537210A5 (enExample) | 2014-11-06 |
Family
ID=44719880
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013528663A Pending JP2013537210A (ja) | 2010-09-16 | 2011-09-14 | １７α−ヒドロキシラーゼ／Ｃ１７，２０−リアーゼ阻害剤 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US8946260B2 (enExample) |
| EP (1) | EP2627648A1 (enExample) |
| JP (1) | JP2013537210A (enExample) |
| CN (1) | CN103108871B (enExample) |
| WO (1) | WO2012035078A1 (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX359399B (es) | 2011-04-28 | 2018-09-27 | Novartis Ag | Inhibidores de 17alfa-hidroxilasa/c17-20-liasa. |
| AR088989A1 (es) * | 2011-11-30 | 2014-07-23 | Hoffmann La Roche | Derivados biciclicos de dihidroisoquinolin-1-ona |
| CN103958478B (zh) * | 2011-11-30 | 2017-08-01 | 霍夫曼-拉罗奇有限公司 | 双环二氢异喹啉‑1‑酮衍生物 |
| AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
| UA111305C2 (uk) | 2012-12-21 | 2016-04-11 | Пфайзер Інк. | Конденсовані лактами арилу та гетероарилу |
| CN104370938A (zh) * | 2013-01-24 | 2015-02-25 | 韩冰 | 一类降低眼压的化合物及其制备方法和用途 |
| CN103086945A (zh) * | 2013-01-24 | 2013-05-08 | 张家港威胜生物医药有限公司 | 一种重要医药化工中间体色胺合成工艺 |
| CN104370926A (zh) * | 2013-01-24 | 2015-02-25 | 韩冰 | 一类具有神经保护作用的化合物及其制备方法和用途 |
| CN104370925A (zh) * | 2013-01-24 | 2015-02-25 | 韩冰 | 一类蛋白酶抑制剂及其制备方法和用途 |
| TWI651317B (zh) * | 2013-05-27 | 2019-02-21 | 赫孚孟拉羅股份公司 | 新穎３，４－二氫－２ｈ－異喹啉－１－酮及２，３－二氫異吲哚－１－酮化合物 |
| RU2693698C2 (ru) * | 2013-05-27 | 2019-07-04 | Ф. Хоффманн-Ля Рош Аг | Новые соединения 3,4-дигидро-2н-изохинолин-1-она и 2,3-дигидроизоиндол-1-она |
| JP6581970B2 (ja) * | 2013-05-27 | 2019-09-25 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 新規３，４−ジヒドロ−２ｈ−イソキノリン−１−オン及び２，３−ジヒドロ−イソインドール−１−オン化合物 |
| JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
| CN106459042B (zh) | 2014-04-02 | 2019-06-28 | 英特穆恩公司 | 抗纤维化吡啶酮类 |
| AP2016009605A0 (en) | 2014-06-17 | 2016-12-31 | Pfizer | Substituted dihydroisoquinolinone compounds |
| US9657015B2 (en) | 2014-07-31 | 2017-05-23 | Boehringer Ingelheim International Gmbh | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity |
| JOP20150177B1 (ar) | 2014-08-01 | 2021-08-17 | Janssen Pharmaceutica Nv | مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2 |
| JOP20150179B1 (ar) | 2014-08-01 | 2021-08-17 | Janssen Pharmaceutica Nv | مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2 |
| JP6689856B2 (ja) | 2014-12-03 | 2020-04-28 | ヤンセン ファーマシューティカ エヌ．ベー． | ６，７−ジヒドロピラゾロ［１，５−ａ］ピラジン−４（５Ｈ）−オン化合物およびＭＧＬＵＲ２受容体の負のアロステリック調節因子としてのそれらの使用 |
| JP6861154B2 (ja) | 2014-12-03 | 2021-04-21 | ヤンセン ファーマシューティカ エヌ．ベー． | 放射標識されたｍＧｌｕＲ２ ＰＥＴリガンド |
| MA41140A (fr) | 2014-12-12 | 2017-10-17 | Cancer Research Tech Ltd | Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg |
| MA41179A (fr) | 2014-12-19 | 2017-10-24 | Cancer Research Tech Ltd | Composés inhibiteurs de parg |
| CA3003998A1 (en) | 2015-12-18 | 2017-06-22 | Janssen Pharmaceutica Nv | Radiolabelled mglur2/3 pet ligands |
| US11045562B2 (en) | 2015-12-18 | 2021-06-29 | Janssen Pharmaceutica Nv | Radiolabelled mGluR2/3 PET ligands |
| CN105541712B (zh) * | 2016-01-08 | 2018-10-09 | 山东金城医药集团股份有限公司 | 索利那新中间体的制备方法 |
| CN108264509B (zh) * | 2016-12-30 | 2021-05-04 | 复旦大学 | 取代的苯并噻吩并[2，3-c]四氢吡啶衍生物及其制备方法和用途 |
| WO2018133865A1 (zh) * | 2017-01-22 | 2018-07-26 | 福建广生堂药业股份有限公司 | Ask1抑制剂及其制备方法和应用 |
| CN108586259A (zh) * | 2018-07-09 | 2018-09-28 | 上海华堇生物技术有限责任公司 | 一种2-甲氧基-β-硝基苯乙烯的新制备方法 |
| CN108929228A (zh) * | 2018-07-09 | 2018-12-04 | 上海华堇生物技术有限责任公司 | 一种3-甲氧基-β-硝基苯乙烯的新制备方法 |
| CN108929229A (zh) * | 2018-07-10 | 2018-12-04 | 上海华堇生物技术有限责任公司 | 一种4-氯-β-硝基苯乙烯的新制备方法 |
| CN114410727B (zh) * | 2022-01-25 | 2023-09-19 | 山东诺明康药物研究院有限公司 | 一种克拉考特酮的制备方法 |
| AR128846A1 (es) | 2022-03-23 | 2024-06-19 | Ideaya Biosciences Inc | Compuestos de indazol sustituidos con piperazina como inhibidores de parg |
| CN117229284B (zh) * | 2023-11-10 | 2024-02-06 | 上海泽德曼医药科技有限公司 | 三环稠杂环类化合物、其制备方法及其在医药上的应用 |
| CN119751453B (zh) * | 2025-01-13 | 2025-10-10 | 浙江工业大学 | 一种n-n轴手性异喹啉酮衍生物的制备方法 |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1524747A (en) | 1976-05-11 | 1978-09-13 | Ici Ltd | Polypeptide |
| ATE28864T1 (de) | 1982-07-23 | 1987-08-15 | Ici Plc | Amide-derivate. |
| GB8327256D0 (en) | 1983-10-12 | 1983-11-16 | Ici Plc | Steroid derivatives |
| ZA882717B (en) | 1987-04-22 | 1988-10-17 | Merrell Dow Pharmaceuticals Inc. | 17beta-(cyclopropylamino)-androst-5-eb-3beta-ol and related compounds useful as c17-20 lyase inhibitors |
| US5093330A (en) | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
| US5010099A (en) | 1989-08-11 | 1991-04-23 | Harbor Branch Oceanographic Institution, Inc. | Discodermolide compounds, compositions containing same and method of preparation and use |
| US4966898A (en) | 1989-08-15 | 1990-10-30 | Merrell Dow Pharmaceuticals Inc. | 4-substituted 17β-(cyclopropylamino)androst-5-en-3β-ol and related compounds useful as C17-20 lyase inhibitors |
| US5395855A (en) | 1990-05-07 | 1995-03-07 | Ciba-Geigy Corporation | Hydrazones |
| WO1992015404A1 (en) | 1991-03-01 | 1992-09-17 | S.L. Electrostatic Technology, Inc. | Powder coating method for producing circuit board laminae and the like |
| NZ243082A (en) | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
| TW219935B (enExample) * | 1991-12-25 | 1994-02-01 | Mitsubishi Chemicals Co Ltd | |
| AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
| US5457102A (en) | 1994-07-07 | 1995-10-10 | Janssen Pharmaceutica, N.V. | Pyrroloimidazolyl and imidazopyridinyl substituted 1H-benzimidazole derivatives |
| CZ287434B6 (en) | 1992-03-31 | 2000-11-15 | British Tech Group | Use of steroids, substituted in position 17, steroids functioning as carcinostatics and pharmaceutical preparation containing thereof |
| TW225528B (enExample) | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
| EP0666868B2 (en) | 1992-10-28 | 2006-06-14 | Genentech, Inc. | Use of anti-VEGF antibodies for the treatment of cancer |
| GB9310635D0 (en) | 1993-05-21 | 1993-07-07 | Glaxo Group Ltd | Chemical compounds |
| GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
| EP0721943A4 (en) | 1993-09-30 | 1996-09-04 | Yamanouchi Pharma Co Ltd | AZOLE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME |
| DK0721461T3 (da) | 1993-09-30 | 1999-09-20 | Btg Int Ltd | Syntese af 17-(3-pyridyl)-steroider |
| WO1996014090A1 (en) | 1994-11-07 | 1996-05-17 | Janssen Pharmaceutica N.V. | Compositions comprising carbazoles and cyclodextrins |
| DE69522717T2 (de) | 1995-03-30 | 2002-02-14 | Pfizer Inc., New York | Chinazolinderivate |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| US5843901A (en) | 1995-06-07 | 1998-12-01 | Advanced Research & Technology Institute | LHRH antagonist peptides |
| US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
| WO1997000257A1 (en) | 1995-06-14 | 1997-01-03 | Yamanouchi Pharmaceutical Co., Ltd. | Fused imidazole derivatives and medicinal composition thereof |
| ATE212993T1 (de) | 1995-07-06 | 2002-02-15 | Novartis Erfind Verwalt Gmbh | Pyrolopyrimidine und verfahren zu ihrer herstellung |
| US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
| GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| HU228446B1 (en) | 1996-04-12 | 2013-03-28 | Warner Lambert Co | Kinazoline derivatives as irreversible inhibitors of protein-kinase, pharmaceutical compositions containing these compounds and use thereof |
| DE69734513T2 (de) | 1996-06-24 | 2006-07-27 | Pfizer Inc. | Phenylamino-substituierte tricyclische derivate zur behandlung hyperproliferativer krankheiten |
| EP0923583A1 (de) | 1996-08-30 | 1999-06-23 | Novartis AG | Verfahren zur herstellung von epothilonen und zwischenprodukte innerhalb des verfahrens |
| EP0938597B1 (en) | 1996-09-06 | 2003-08-20 | Obducat Aktiebolag | Method for anisotropic etching of structures in conducting materials |
| DE19638745C2 (de) | 1996-09-11 | 2001-05-10 | Schering Ag | Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR) |
| WO1998010767A2 (en) | 1996-09-13 | 1998-03-19 | Sugen, Inc. | Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders |
| EP0837063A1 (en) | 1996-10-17 | 1998-04-22 | Pfizer Inc. | 4-Aminoquinazoline derivatives |
| ES2312695T3 (es) | 1996-11-18 | 2009-03-01 | Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) | Epotilones e y f. |
| US6441186B1 (en) | 1996-12-13 | 2002-08-27 | The Scripps Research Institute | Epothilone analogs |
| CO4950519A1 (es) | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
| CO4940418A1 (es) | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
| EP1028110B1 (en) | 1997-10-02 | 2004-04-14 | Daiichi Pharmaceutical Co., Ltd. | Novel dihydronaphthalene compounds and process for producing the same |
| GB9721069D0 (en) | 1997-10-03 | 1997-12-03 | Pharmacia & Upjohn Spa | Polymeric derivatives of camptothecin |
| US6194181B1 (en) | 1998-02-19 | 2001-02-27 | Novartis Ag | Fermentative preparation process for and crystal forms of cytostatics |
| IL138113A0 (en) | 1998-02-25 | 2001-10-31 | Sloan Kettering Inst Cancer | Synthesis of epothilones, intermediates thereto and analogues thereof |
| CA2328973A1 (en) | 1998-04-23 | 1999-10-28 | Akio Ojida | Naphthalene derivatives, their production and use |
| WO2000009495A1 (en) | 1998-08-11 | 2000-02-24 | Novartis Ag | Isoquinoline derivatives with angiogenesis inhibiting activity |
| GB9824579D0 (en) | 1998-11-10 | 1999-01-06 | Novartis Ag | Organic compounds |
| UA71587C2 (uk) | 1998-11-10 | 2004-12-15 | Шерінг Акцієнгезелльшафт | Аміди антранілової кислоти та їхнє застосування як лікарських засобів |
| US6303342B1 (en) | 1998-11-20 | 2001-10-16 | Kason Biosciences, Inc. | Recombinant methods and materials for producing epothilones C and D |
| DK1140173T4 (da) | 1998-12-22 | 2013-06-10 | Genentech Inc | Vaskulære endothelcellevækstfaktorantagonister og anvendelser deraf |
| PT1165085E (pt) | 1999-03-30 | 2006-10-31 | Novartis Ag | Derivados de ftalazina para tratar doencas inflamatorias |
| TWI238824B (en) | 2001-05-14 | 2005-09-01 | Novartis Ag | 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives |
| GB0119249D0 (en) | 2001-08-07 | 2001-10-03 | Novartis Ag | Organic compounds |
| US20040198773A1 (en) | 2001-09-26 | 2004-10-07 | Barry Hart | Substituted 3-pyridyl oxazoles as c17,20 lyase inhibitors |
| GB0418900D0 (en) | 2004-08-24 | 2004-09-29 | Btg Int Ltd | Novel salt forms |
| EA019560B1 (ru) | 2005-03-02 | 2014-04-30 | Юнивесити Оф Мэриленд, Балтимор | Способ лечения простаты (варианты) |
| CA2838089A1 (en) | 2006-08-25 | 2008-02-28 | Cougar Biotechnology, Inc. | Methods for treating cancer comprising the administration of a vitamin d compound and an additional therapeutic agent, and compositions containing the same |
| JP2008273924A (ja) * | 2007-03-30 | 2008-11-13 | Meiji Seika Kaisha Ltd | ２位チエニルカルバペネム誘導体 |
| CN101084881B (zh) | 2007-06-23 | 2012-08-29 | 淮北辉克药业有限公司 | 靶向速释泡腾制剂及其制备方法 |
| WO2009081579A1 (ja) | 2007-12-26 | 2009-07-02 | Nippon Soda Co., Ltd. | 含窒素複素環化合物および農園芸用殺菌剤 |
| ES2401059T3 (es) * | 2008-06-23 | 2013-04-16 | H. Lundbeck A/S | Derivados de isoquinolinona como antagonistas de NK3 |
| TW201039822A (en) * | 2009-02-06 | 2010-11-16 | Taisho Pharmaceutical Co Ltd | Dihydroquinolinone derivatives |
| UY32730A (es) | 2009-06-26 | 2011-01-31 | Novartis Ag | Inhibidores de cyp17 |
| US8846656B2 (en) * | 2011-07-22 | 2014-09-30 | Novartis Ag | Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators |
-
2011
- 2011-09-14 EP EP11761540.1A patent/EP2627648A1/en not_active Withdrawn
- 2011-09-14 US US13/823,792 patent/US8946260B2/en not_active Expired - Fee Related
- 2011-09-14 CN CN201180044494.8A patent/CN103108871B/zh not_active Expired - Fee Related
- 2011-09-14 JP JP2013528663A patent/JP2013537210A/ja active Pending
- 2011-09-14 WO PCT/EP2011/065965 patent/WO2012035078A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013537210A5 (enExample) | ||
| RU2470023C2 (ru) | 1-цианоциклопропильные производные в качестве ингибиторов катепсина к | |
| KR101626435B1 (ko) | Ｐｉ３ｋ 알파의 피리도피리미디논 억제제를 이용한 암 치료 방법 | |
| JP2020514267A5 (enExample) | ||
| JP2010522750A5 (enExample) | ||
| JP2015511245A5 (enExample) | ||
| JP2014528479A5 (enExample) | ||
| RU2020124136A (ru) | Производные хроменопиридина в качестве ингибиторов фосфатидилинозитолфосфаткиназы | |
| JP2013522354A5 (enExample) | ||
| JP2018507214A5 (enExample) | ||
| JP2001097889A (ja) | Ｃｒｆアンタゴニストおよび関連組成物の使用 | |
| RU2018112230A (ru) | Бициклические соединения в качестве ингибиторов atx | |
| KR20190080897A (ko) | 치환된 피리디논 함유 트리시클릭 화합물, 및 그의 사용 방법 | |
| RU2016130932A (ru) | Производные хинолона как ингибиторы рецептора фактора роста фибробластов | |
| WO2017214458A4 (en) | Anti-cd98 antibodies and antibody drug conjugates | |
| JP2014510037A5 (enExample) | ||
| JP2014533734A5 (enExample) | ||
| KR20180030199A (ko) | 콜로니 자극 인자-1 수용체(csf-1r) 저해제 | |
| JP2013521285A5 (enExample) | ||
| CA2504385A1 (en) | Thiadiazine compounds and uses thereof | |
| JP2014503544A5 (enExample) | ||
| JP2017531039A5 (enExample) | ||
| JP2023548657A (ja) | がんの処置に使用するための、ｅｇｆｒおよび／またはｈｅｒ２のヘテロ環阻害剤 | |
| RU2013143292A (ru) | Триазолопиридиновые соединения как ингибиторы киназы pim | |
| JP2016537384A5 (enExample) |